Salarius Pharmaceuticals, Inc. (SLRX) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Daniela, if you want to chime in. So these patients, as you mentioned, were heavily pre-treated. They got multiple lines of treatment. And so if they had not received seclidemset, you would not have seen that stable disease. These patients typically, without treatment, unfortunately don't live that long. So the stable disease, if you will, for these patients would have been less than a couple of months or less. what happens with these patients is once they fail all standard treatments, especially for FET, translocated sarcoma, there is no specific one treatment. So they may either get back on some chemotherapy, which is usually very toxic for these patients. Again, I think for a single agent to show stabilization for greater than, majority of the patients, greater than six months, gives us a very good early signal. If you remember, in that advanced solid tumor, they were very late-stage patients. In our current expansion phase, we have limited the number of prior lines of treatment they could receive, so they could receive up to three prior lines of treatment, which means that we could enroll a fourth-line patient. So we hope that if you enroll patients that are early lines of treatment, we would expect to see a longer stabilization of disease, which will translate into a longer... progression-free survival. That's the strategy we are following, using the phase one data to inform us on which patient population to further explore in the phase two. And so based on that, we currently have this expansion phase, which has two different FET translocated sarcomas, one for myxoid and the other one for FET specifically. Okay. All right. Thank you very much. I appreciate all the answers, and again, congratulations for the quorum. Thank you. Your next question from Mike King, F...